Correspondence on ‘Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)’ by Imai et al
Correspondence on ‘Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)’ by Imai et al. // Annals of the Rheumatic Diseases. – URL: https://www.sciencedirect.com/science/article/pii/S0003496726002724?dgcid=rss_sd_all
Correspondence on ‘Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)’ by Imai et al. Annals of the Rheumatic Diseases. https://www.sciencedirect.com/science/article/pii/S0003496726002724?dgcid=rss_sd_all
“Correspondence on ‘Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)’ by Imai et al.” Annals of the Rheumatic Diseases.
@article{article35864,
title = {Correspondence on ‘Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)’ by Imai et al},
journal = {Annals of the Rheumatic Diseases},
url = {https://www.sciencedirect.com/science/article/pii/S0003496726002724?dgcid=rss_sd_all}
}